RxDoctor Payments Data

Kyla Halsor, MD

Family Medicine · Las Cruces, NMNPI 1225531098

Payments from drug & device makers

$1,406in general payments, 2019–2025

Across 46 payments — averaging $30.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$473
  • Novo Nordisk$190
  • Lilly USA, LLC$140
  • Amgen$112
  • Nalu Medical, Inc.$112
  • GSK$110
  • plus $270 from 7 others

What the payments were for

  • Food & beverage$1,406100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,406 in reported general payments places this provider in the 85th percentile of 717 family medicine providers in New Mexico.

See all family medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$62,515
Medicare patients
175
Services billed
865

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide25$33,457
MounjaroTirzepatide22$25,703
EliquisApixaban16$23,763
JardianceEmpagliflozin13$16,225
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$4,671
Gabapentin45$1,156
Atorvastatin Calcium107$1,081
Levothyroxine Sodium83$1,051
Omeprazole39$717
Albuterol Sulfate HfaAlbuterol Sulfate25$634
Simvastatin33$629
Losartan Potassium47$551
Rosuvastatin Calcium28$531
Lisinopril66$514
Cyclobenzaprine Hcl26$489

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$190$33,45725 claims
Lilly USA, LLCMounjaro$140$25,70322 claims
PfizerEliquis$102$23,76316 claims
Boehringer IngelheimJardiance$19$16,22513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 717 family medicine providers in New Mexico.

Other family medicine in Las Cruces

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →